All News

One-year open-label MINT data show sustained MG-ADL and QMG score gains with inebilizumab, including in patients who switched from placebo.

Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.

Real-world study tracks JAK inhibitors in alopecia areata and atopic dermatitis, flagging menstrual alterations and weight gain as key safety signals.

Proposals to drop race questions from the 2030 census and end EEOC workforce reporting could leave gaps in national racial data.

SGLT2 inhibitors were linked to hemoglobin gains of about 1.0 to 1.6 g/dL in small MDS and MPN studies, but a review found no randomized trials to confirm.

Experts at GOLD 2026 say targeted case finding, AI, and guideline-based treatment can close COPD’s diagnostic gap and improve patient outcomes.

Phase 3 hepatitis delta data, MASH persistence and cost findings, and new PBC treatment targets led The Liver Meeting 2026 in Denver, Colorado.

A prospective Italian study of 492 postmenopausal women found ultrasound signs of deep endometriosis in 7.3%, often plaque-like and poorly vascularized.

AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.

In this Q&A, Rob Stransky of NiceRx explains how to screen patients for gray-market retatrutide use and why cost drives demand for unregulated peptides.

First-line IVF produced more live births than IUI within 7 months in couples with unexplained infertility.

Elafibranor and seladelpar normalized ALP in most patients with primary biliary cholangitis whose ALP was below the usual escalation threshold.

The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.

Most patients with MASH stay on resmetirom at 1 year, but Medicaid coverage was tied to lower odds of filling a first prescription within 30 days.

A 20-year review traces how immune checkpoint inhibitors became a cornerstone of lung cancer treatment.

David T. Plante, MD, PhD, explains that separating mood-related sleepiness from primary hypersomnia relies on the course of illness and sleep testing.

Diabetes and functional dependence predicted 3-year graft loss after MASH liver transplant, while machine learning showed limited predictive power.

In nonobese patients in the ESSENCE trial, semaglutide improved metabolic dysfunction even with modest weight loss of 2% to 5%.

Weill Cornell's Mateo Mejia Saldarriaga, MD, explains why oral options like iberdomide and clinical trials matter in the immunotherapy era of myeloma.

Phase 3 Viti-Up trials show Rinvoq (upadacitinib) JAK inhibitor boosts facial and body repigmentation in nonsegmental vitiligo, with familiar safety.

A population-based study of 1102 Canadian children found infants with bone and soft tissue tumors had poorer survival, driven largely by treatment deaths.

Liver disease disparities tied to insurance and race spanned HCC surveillance, transplant listing, and drug access in data at The Liver Meeting 2026.

Started at advanced fibrosis or cirrhosis, pegozafermin lowered liver collagen below baseline and prevented liver cancer in a MASH mouse model.

A case report describes the first KRAS::ETNK1 fusion in MDS/MPN with eosinophilia; the fusion disappeared when the disease relapsed as AML.

Hepatitis B functional cure with bepirovirsen held in 90% to 92% of responders 48 weeks after stopping all therapy, per data at The Liver Meeting 2026.

GOLD leaders say COPD is diagnosed too late and its smoking-only image is outdated, and the 2027 report puts rehab and non–drug care up front.

Most patients with CLL/SLL who discontinued a first-line BTK inhibitor did not start second-line therapy, and older age was linked to worse outcomes.

Resmetirom real-world data at The Liver Meeting 2026 show 12-month gains in liver stiffness, fat, and enzymes among patients with MASH in 3 US data sets.